Free Trial

LENZ Therapeutics Q3 2024 Earnings Report

LENZ Therapeutics logo
$23.82 +1.32 (+5.87%)
As of 01/21/2025 04:00 PM Eastern

LENZ Therapeutics EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.47
Beat/Miss
Beat by +$0.09
One Year Ago EPS
-$1.33

LENZ Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LENZ Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens

LENZ Therapeutics Earnings Headlines

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
LENZ Therapeutics: Time For A Pause
See More LENZ Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email.

About LENZ Therapeutics

LENZ Therapeutics (NASDAQ:LENZ), a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

View LENZ Therapeutics Profile

More Earnings Resources from MarketBeat